OXLUMO (LUMASIRAN)
OXLUMO (LUMASIRAN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: OXLUMO; Generic name: LUMASIRAN; Manufacturer: Alnylam Pharmaceuticals, Inc..
| Brand name | OXLUMO |
|---|---|
| Generic name | LUMASIRAN |
| Manufacturer | Alnylam Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] . OXLUMO is a HAO1 -directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dose of OXLUMO by subcutaneous injection is based on body weight. ( 2.1 ) Body Weight Loading Dose Maintenance Dose less than 10 kg 6 mg/kg once monthly for 3 doses 3 mg/kg once monthly, beginning 1 month after the last loading dose 10 kg to less than 20 kg 6 mg/kg once monthly for 3 doses 6 mg/kg once every 3 months (quarterly), beginning 1 month after the last loading dose 20 kg and above 3 mg/kg once monthly for 3 doses 3 mg/kg once every 3 months ( |
| Active ingredient(s) | LUMASIRAN SODIUM |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16985a31-f5e4-4557-9266-fc78d4bc5055 |